Oppenheimer Assumes Kempharm (KMPH) at Outperform

Oppenheimer analyst Esther Rajavelu assumes coverage on Kempharm (NASDAQ: KMPH) with a Outperform rating and a price target of $13.00.

The analyst comments "We remain positive on KMPH's ligand activated therapy (LAT) pro-drug platform and believe it has broad applicability in pain and CNS indications. We note management has met KP415/484 clinical milestones in the recent weeks, and has positioned the company well to execute a partnership and regulatory filings. While management continues to execute on all fronts, including the potential 1Q19 NDA filing of KP415 and potential commercialization of Apadaz in 2019, we believe the stock could remain under pressure until there is clarity on the commercial strategy for its portfolio."

For an analyst ratings summary and ratings history on Kempharm click here. For more ratings news on Kempharm click here.

Shares of Kempharm closed at $4.95 yesterday.

You May Also Be Interested In

• Deutsche Bank Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
• DA Davidson Starts QXO Inc (QXO) at Neutral
• JBS SA (JBS) PT Raised to $17.50 at UBS